Although the rational use of HF drugs—including angiotensin receptor-neprilysin inhibitors, β-adrenergic receptor antagonists, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors—can robustly reduce morbidity and mortality in the majority of patients with HF, [2] the economic burden of the non-elderly living with HF has grown following a surge in obesity and obesity-related diseases and constitutes an alarming and ominous sign [3,7]. The gene discussed is SLC5A2; the disease is hydrops fetalis.